bioRxivCell BiologyPreprint
Human Lung Alveolar Model with an Autologous Innate and Adaptive Immune Compartment
Linda SteinacheriD, Bruno Gjeta, Marisa Pimentel MendesiD, Floriana CremascoiD, Irineja Cubela, Marina BellavistaiD, Laura Gaspa-ToneuiD, Luisa Lauer, Qianhui YuiD, Ryo Okuda, Barzin Y. NabetiD, Velimir GayevskiyiD, Michel SiegeliD, Axel DucretiD, Evodie Lassalle, Giacomo Lazzaroni, Jonas M. NikoloffiD, Miguel Camacho RufinoiD, Christelle Zundel, Leo KunziD, Tamara Zimmermann, Bilgenaz StolliD, Cyrill Roth, Adrian B. RothiD, Rajat MohindraiD, , Lauriane CaboniD
Abstract
Lung-resident immune cells, spanning both innate and adaptive compartments, preserve the integrity of the respiratory barrier, but become pathogenic if dysregulated1. Current in vitro organoid models aim to replicate interactions between the alveolar epithelium and immune cells but have not yet incorporated lung-specific immune cells critical for tissue residency2. Here we address this shortcoming by describing human lung alveolar immuno-organoids (LIO) that contain an autologous tissue-resident lymphoid compartment, primarily composed of tissue-resident memory T cells (TRMs). Additionally, we introduce lung alveolar immuno-organoids with myeloid cells (LIOM), which include both TRMs and a macrophage-rich alveolar myeloid compartment. The resident immune cells formed a stable immune-epithelial system, frequently interacting with the epithelium and promoting a regenerative alveolar transcriptomic profile. To understand how dysregulated inflammation perturbed the respiratory barrier, we simulated T-cell-mediated inflammation in LIOs and LIOMs and used single-cell transcriptomic analyses to uncover the molecular mechanisms driving immune responses. The presence of innate cells induced a shift in T cell identity from cytotoxic to immunosuppressive, reducing epithelial cell killing and inflammation. Based on insights obtained with bulk RNA-seq data from the phase 3 IMpower150 trial, we tested whether LIOM cultures could model clinically-relevant but poorly understood pulmonary side effects caused by immunotherapies such as the checkpoint inhibitor atezolizumab3. We observed a decrease in immunosuppressive T cells and identified gene signatures that matched the transcriptomic profile of patients with drug-induced pneumonitis. Given its effectiveness in capturing outcomes and mechanisms associated with a prevalent pulmonary disease, this system unlocks opportunities for studying a wide range of immune-related pathologies in the lung.
- organism: human
- assay: scRNA-seq
- research focus: cell type annotation
- research focus: differential expression
- research focus: cell-cell communication
- approach: experimental assay
- Citations
- 4
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A human organoid model of alveolar regeneration reveals distinct epithelial responses to interferon-gamma
Antonella F. M. Dost, Katarína Balážová, … Hans C. Clevers·The EMBO JournalPeer-reviewed·Apr 16, 2026
- Donor tissue-resident memory-like T and NK cells generate a transient peripheral chimerism in lung transplant recipients, potentially protective from chronic lung allograft dysfunction
R. Bellmas-Sanz, A.-M. Hitz, … C. S. Falk·bioRxiv·Jun 16, 2023
- Emergence of a senescent and inflammatory pulmonary CD4+ T cell population prior to lung allograft failure
S. Moshkelgosha, L. Levy, … S. Juvet·bioRxiv·Dec 19, 2023
- Induced microfold cells are required for the function of pulmonary tertiary lymphoid organs that promote mucosal immunity
Manalee Vishnu Surve, Dawei Sun, … Jayaraj Rajagopal·bioRxiv·Nov 2, 2026
- Ex vivo delivery of regulatory T cells for control of alloimmune priming in the donor lung
E. Miyamoto, A. Takahagi, … S. C. Juvet·bioRxiv·Feb 7, 2021
- Interferon-stimulated and metallothionein-expressing macrophages are associated with acute and chronic allograft dysfunction after lung transplantation
S. Moshkelgosha, A. Duong, … S. C. Juvet·bioRxiv·Jun 14, 2021